Sequest

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sequest

Property Description
Active Ingredient Cholestyramine (Colestyramine)
Form Powder for Oral Suspension
Pharmacological Class Bile Acid Sequestrant (Hypolipidemic Agent)
General Purpose To help reduce elevated cholesterol levels
Origin Synthetic Polymeric Compound

What Type of Medicine is Sequest and What is its Composition?

Sequest is a prescription pharmaceutical preparation whose active ingredient is cholestyramine, classified as a bile acid sequestrant and a hypolipidemic agent. Chemically, cholestyramine is a synthetic polymeric compound that functions as a strong anion exchange resin. The medicine is defined as a non-absorbed resin, meaning it is designed to act exclusively within the gastrointestinal tract and not enter the bloodstream.

The substance, often referred to as Colestyramine, is the chloride salt of a basic anion exchange resin. This chemical structure dictates the drug’s non-systemic mode of action. Unlike similar oral lipid-lowering agents, cholestyramine's efficacy is based on its physical binding capacity. This non-systemic approach ensures that the drug's effect is confined to the digestive system, facilitating its primary function through a localized chemical interaction.


What is the Purpose and Physical Form of Cholestyramine?

The general purpose of Sequest is to help lower high levels of certain fats in the blood, primarily by interrupting the recycling of compounds essential for fat management. Sequest is supplied as a distinctive powder for oral suspension, requiring the patient to mix the dry formulation with water, juice, or another suitable fluid immediately prior to its oral administration. This form differentiates it from many standard tablet-based prescription medicines.

This benefit arises from the drug's capacity for binding to bile acids in the intestine. The cholestyramine resin chemically attracts and holds onto these acids, forming a stable, insoluble complex that is then passed out of the body. Bile acid sequestrants are recognized for interrupting the enterohepatic circulation, a process which forces the body to use available circulating cholesterol to synthesize new bile acids, thereby achieving the intended lipid-lowering effect.

Regulatory References

  1. Cholestyramine - LiverTox - NIH

What side effects are possible with Sequest?

Possible Side Effects and Safety Information

The official safety profile for Sequest, which contains cholestyramine, is primarily characterized by effects related to its non-absorbed action as a bile acid sequestrant within the gastrointestinal tract. Regulatory documents classify and organize possible adverse reactions by frequency and the body system affected.


Frequency-Classified Adverse Reactions

The most frequently documented effects involve the digestive system. Very Common adverse reactions include constipation, flatulence, and nausea. Common adverse reactions typically include vomiting, diarrhea, and abdominal discomfort or pain. Hypersensitivity reactions, such as rash or urticaria, are generally classified as Uncommon.


System-Organ Classes and Serious Safety Concerns

The primary system-organ class involved is Gastrointestinal Disorders. The label also documents Metabolism and Nutrition Disorders because the binding mechanism can potentially impair the absorption of certain nutrients. For instance, deficiencies in fat-soluble vitamins (A, D, E, K) and folic acid are associated with long-term exposure.

Regulatory sources explicitly list rare but serious adverse reactions, including complete or partial intestinal obstruction and an increased bleeding tendency due to hypoprothrombinemia (Vitamin K deficiency).


Population-Specific Safety Notes

Specific regulatory constraints exist for certain populations. Older adults are noted as having an increased risk for severe constipation and subsequent fecal impaction. Additionally, the medicine is formally contraindicated in individuals with pre-existing complete biliary obstruction or intestinal obstruction.

Overdose and Emergency Response

The regulatory documentation on Sequest (Cholestyramine) overdose is structured around the medicine's pharmacological properties, which result in non-systemic absorption. Consequently, the primary potential manifestation of overdosage is cited as the obstruction of the gastrointestinal tract. This can clinically present as an acute abdominal symptom complex. Past regulatory reports indicate that this condition has been identified via diagnostic findings, such as a "pasty mass" detected within the colon.

A significant concern highlighted in official safety records is the potential for a severe, life-threatening outcome. Although rare, cases of intestinal obstruction have been reported, including documented fatalities. Regulatory records specifically note that pediatric patients are a population where these severe outcomes have been associated with post-marketing surveillance.

In the event of a suspected overdose, official guidance mandates that individuals seek immediate medical attention and contact a poison control center. Treatment is defined as symptomatic and supportive, consistent with the finding that no specific antidote is known. Key official management procedures involve assessing the degree of obstruction and monitoring for abdominal pain or distention.

Therapeutic Uses of Sequest

Sequest is commonly used in clinical settings involving systemic imbalance and supportive symptom management for a variety of conditions. The medication helps address symptoms that create noticeable physiological strain, and is considered relevant for easing symptoms that interfere with daily functioning and routine.

The medicine assists in managing conditions characterized by periods of symptoms that may intensify temporarily, episodic or fluctuating manifestations, and those presenting with systemic or localized discomfort. This is often used when symptoms intensify and supportive relief is needed. The goal of this support is to provide symptomatic relief that helps patients cope more steadily.


Easing Symptom Burden and Supporting Stability

This therapeutic domain is applied across domains where additional symptomatic support is needed. It provides short-term assistance that supports general well-being and provides support that helps ease the overall symptom load during acute or disruptive episodes. It assists with maintaining functional stability and contributes to comfort during periods of heightened symptoms marked by increased discomfort or tension.

Quick Fact: Support for Symptoms of Physiological Strain

Regulatory References

  1. NIH MedlinePlus overview of Bile Acid Sequestrants

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Sequest

Sequest (Cholestyramine) is subject to strict eligibility rules documented in official regulatory labeling. Use is contraindicated in two key populations:

  • Patients with complete biliary obstruction, as the medicine's non-systemic binding action requires bile to be present in the intestine.
  • Individuals with known hypersensitivity or allergy to cholestyramine or any component of the formulation.

Eligibility Status by Population

Category Regulatory Status
Use Not Recommended Patients with baseline fasting triglyceride levels ge 400 mg/dL or severe hypertriglyceridemia, due to risk of increased levels.
Age-Related Restrictions Children under 6 years are generally ineligible because safety and effectiveness have not been established.
Conditional Use Pregnant or breastfeeding individuals may use the medicine only if the benefit outweighs the potential hazard, primarily due to the risk of impaired absorption of fat-soluble vitamins (A, D, E, K).
Comorbidity Caution Caution is required in patients with pre-existing constipation (may be worsened) or renal impairment (risk of hyperchloremic acidosis).

Official regulatory documents define non-eligibility by establishing absolute prohibition based on physiological function and explicit contraindications for severe metabolic conditions. Use is permitted under conditional terms for eligible age groups and life stages, where the primary restriction involves careful monitoring to mitigate nutritional deficiencies or exacerbation of gastrointestinal issues.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Sequest (Cholestyramine) is a non-absorbed resin, and its official interaction profile is characterized by pharmacokinetic binding in the gastrointestinal tract, which affects the systemic exposure of co-administered oral medicines. This mechanism is cited in regulatory documents as the primary interaction concern.

Documented Pharmacokinetic and Nutrient Interactions

Interaction Type Interacting Substances (Examples) Official Regulatory Statement
Reduced Absorption Warfarin, Thyroxine, Digoxin, Thiazide Diuretics, Propranolol, Oral Contraceptives, NSAIDs Co-administration results in decreased systemic absorption and potentially lower plasma concentrations.
Nutrient Interference Fat-Soluble Vitamins (A, D, E, K), Folic Acid Long-term administration interferes with absorption, carrying the risk of hypoprothrombinemia due to Vitamin K deficiency.
Pharmacodynamic HMG-CoA Reductase Inhibitors (Statins) Officially documented to produce an additive lipid-lowering effect on cholesterol levels.

Regulatory Constraints and Timing

To prevent the resin from binding and reducing the absorption of other oral medications, official prescribing information mandates a timing separation rule. Patients must administer other oral medicines at least one hour before OR 4 to 6 hours after taking Sequest.

Population-specific interaction notes include an increased risk of hyperchloremic acidosis for younger or smaller patients and those with renal insufficiency, linked to the drug's chloride content.

Mechanism of Action

Localized Sequestration in the Intestinal Lumen

This mechanism begins with the drug's role as a non-absorbed resin, which physically binds to bile acids in the gastrointestinal tract, preventing their normal reabsorption and forcing their increased excretion from the body. This local action serves as the molecular trigger for the entire subsequent physiological cascade.

Hepatic Feedback and LDL Receptor Upregulation

The resulting deficit in the liver's bile acid pool forces the acceleration of new bile acid synthesis, demanding the rapid consumption of internal hepatic cholesterol stores. In response to this depletion, the liver dramatically increases the surface expression of its Low-Density Lipoprotein (LDL) receptors.

Systemic Enhancement of Plasma Clearance

The enhanced density of LDL receptors increases the liver's capacity to internalize circulating LDL-cholesterol from the plasma. This increased clearance activity is the systemic consequence of the mechanistic cascade, resulting in an alteration of plasma lipoprotein concentrations.

Dosage and Administration Information

How to use Sequest

The usage of the medicine is defined by specific procedures for its non-systemic oral administration. This framework ensures proper handling, preparation, and timing relative to other treatments.

Administration Scope

Instruction Category Guideline
Route of Administration Oral administration only.
Dosing Schedule (Adults) Standard Unit: 4 g of anhydrous cholestyramine resin. Initial Dose: 4 g once or twice daily. Maximum Dose: 24 g/day.
Timing in Relation to Meals Suggested administration is generally at mealtime.
Preparation Requirements The powder must be mixed with 60 to 180 mL (2 to 6 ounces) of water, juice, or non-carbonated fluid before ingestion; it is not to be taken in dry form.
Age-Group Administration Rules Pediatric Dose: 240 mg/kg/day of cholestyramine in 2 to 3 divided doses, not to exceed 8 g/day.
Missed-Dose Rules If a dose is missed, patients should simply resume the next scheduled dose at the regular time; do not double the dose.
Special Procedural Conditions Drug Separation: Other oral medications must be taken at least 1 hour before or 4 to 6 hours after Sequest. Titration: Dose increases should be gradual, typically at intervals of not less than 4 weeks.

Instruction Classifications (High-Level)

Classification Detail
Administration method type Oral suspension (Reconstituted powder).
Frequency pattern Once daily, or divided into 2 to 6 doses per day.
Regulatory basis Based on clinical prescribing information.
Use-context constraints Requires strict separation from other medications and specific liquid preparation.

The administration protocol for Sequest defines a structured use pattern centered on its physical delivery to the digestive tract. Instructions include specific fluid preparation and timing relative to other oral drugs and meals, establishing a framework for how the resin is administered. This procedure dictates the daily frequency and the long-term schedule, including specified intervals for gradual dose adjustments.

Recent Clinical Evidence

Research evidence / Overview of Studies for Sequest

This overview summarizes the key types of research studies that have evaluated clinical outcomes with Sequest (cholestyramine), drawing solely from authoritative governmental and peer-reviewed scientific sources. The text focuses on what research examined and what findings were described, without offering clinical advice or making claims about individual outcomes.


Evidence for Use in Lowering Cholesterol (Primary Hypercholesterolemia)

This section summarizes the structure of the foundational clinical research, including the large-scale Randomized Controlled Trials (RCTs) that evaluated changes in lipid biomarkers and major cardiovascular events.

Early and foundational research into Sequest primarily focused on high cholesterol levels. Large-scale RCTs were conducted during periods of increased symptom activity and followed participants over several years. These studies specifically monitored the incidence of major cardiovascular events, which are outcomes related to systemic or functional imbalance. Researchers also evaluated changes in specific blood lipid biomarkers, including LDL-C and Total Cholesterol.

Findings from these trials described patterns observed in the studies regarding the tracked lipid biomarkers and major coronary events. This evidence contributes to the broader evidence landscape regarding agents that were studied for their effect on cholesterol. However, the most significant long-term primary prevention trial was the primary prevention trial for hypercholesterolemia, where participants were observed in study settings for approximately seven years. Consequently, the results apply only to the populations studied, and the long-term outcomes for women and other segments are not as well characterized. Challenges with adherence due to the preparation's characteristics were noted as a factor in certain study conclusions.

Evidence for Symptom Management in Biliary Obstruction (Pruritus)

This block will describe the types of research, such as smaller RCTs and systematic reviews, that investigated measurements related to itching (pruritus) associated with partial biliary obstruction, and the specific outcomes that were measured.

Research has explored the use of Sequest in conditions characterized by fluctuating or episodic manifestations, specifically the severe itching (pruritus) associated with partial biliary obstruction. Studies for this condition were typically short-term RCTs that applied in studies examining patient-reported experiences. The primary focus was on patient-reported outcomes describing perceived discomfort, often using scales to measure the intensity and frequency of itching. The research contributes to understanding symptom patterns in patients experiencing outcomes related to physical discomfort.

Key Studies & References

  1. Clinical guidelines on the identification, evaluation, and treatment of high blood cholesterol in adults: summary of the evidence
  2. Cholestyramine as a therapeutic option in refractory thyrotoxicosis
  3. Hypolipidemic Agents: Bile Acid Sequestrants

Frequently Asked Questions (FAQ)

Common questions about Sequest (FAQ)

Q: What are the most common reasons doctors prescribe Sequest?

A: The medication is approved by regulatory bodies to help lower elevated cholesterol levels (hyperlipidemia). It is also officially indicated for the treatment of the itching (pruritus) associated with partial biliary obstruction.


Q: Is Sequest used to treat things other than what is listed in the main uses?

A: Yes, official regulatory documents confirm that in addition to managing high cholesterol, the medication is indicated for the treatment of itching (pruritus) caused by partial biliary obstruction. This addresses a symptom documented for patients with this specific condition.


Q: Is there a generic version of Sequest available yet?

A: Yes, the active ingredient in Sequest, known as cholestyramine, is available in generic formulations. These generic versions are authorized by regulatory bodies as having the same active ingredient as the brand-name products.


Q: What is meant by the 'mechanism of action' for Sequest in simple language?

A: The medication is a non-absorbed resin that works locally in the intestines by physically binding to bile acids. This process prevents the bile acids from being recycled. This process then prompts the liver to use cholesterol from the bloodstream to create new bile acids, thereby helping to lower cholesterol levels.


Q: How long does it typically take for a person to start noticing effects from Sequest?

A: The measurable lipid-lowering effects of the medication are typically assessed through laboratory blood tests. These tests are usually conducted approximately four to six weeks after starting the therapy.


Q: What is the time window for taking Sequest each day?

A: There is no strict daily time window for administration. Official guidelines generally suggest administration at mealtime, and the total daily dose may be divided into one to six doses per day.


Q: Can Sequest be taken with milk or juice?

A: Yes, the powder must be mixed with a fluid before ingestion to prevent potential choking hazards. The fluid can include water, fruit juices, or milk.


Q: Can Sequest be crushed, split, or chewed?

A: The medication is supplied as a powder for oral suspension. Regulatory information specifies that the powder formulation is required to be mixed with fluid before ingestion and should not be taken dry, split, or chewed.


Q: Can I take vitamins or herbal supplements while using Sequest?

A: The medication can interfere with the absorption of certain vitamins and other oral products due to its binding action in the intestine. Official guidance suggests separating the administration of vitamins and supplements by at least one hour before or four to six hours after taking Sequest.


Q: How long does Sequest stay in your system after the last pill?

A: The active ingredient in Sequest is a non-absorbed resin, meaning it is designed to act locally within the intestine and does not enter the bloodstream. The drug forms a stable complex that is then excreted from the body via the feces.


Q: Does Sequest change how I metabolize caffeine or alcohol?

A: Regulatory sources state it is unknown if drinking alcohol will directly affect the medication itself. However, alcohol consumption may worsen side effects such as dizziness or lightheadedness, and both can increase the risk of bleeding.


Q: Does Sequest affect my ability to drive or operate machinery?

A: Official patient information indicates that caution may be necessary when driving or operating heavy machinery. This is because the medication may cause light-headedness, dizziness, drowsiness, or tiredness in some individuals.


Q: Is it common to feel tired when starting Sequest?

A: Official patient information states that drowsiness, tiredness, or light-headedness may occur in some people. Patients may need to exercise caution until they understand how the medicine affects them.


Q: What happens if I stop taking Sequest suddenly?

A: Regulatory information states that stopping the medication without consulting a healthcare provider may lead to an increase in blood cholesterol levels again after treatment is discontinued.


Q: Does Sequest have a withdrawal period when stopping the medicine?

A: There is no reported physical withdrawal syndrome associated with this drug. However, if the medication is stopped, blood cholesterol levels may increase and return to prior elevated levels.


Q: Is Sequest addictive or habit-forming?

A: This medication is classified as a bile acid sequestrant and is not designated as a controlled or habit-forming substance.


Q: Is Sequest a controlled substance?

A: No, the medication is not classified as a controlled substance by U.S. regulatory bodies.


Q: Why is Sequest not approved for use in children?

A: For children under six years of age, official regulatory bodies have determined that the safety and effectiveness of this medication have not been established.


Q: Can older adults use Sequest safely?

A: Official patient information notes that side effects, particularly severe constipation, are reported to be more likely in older adults (over 60 years of age). Regulatory documents note that this risk factor may be more pronounced in older patients.


Q: Can men and women use Sequest with the same expectations?

A: Research documentation notes that long-term outcomes were not as well characterized for women compared to the male populations involved in the foundational primary prevention studies.


Q: Can people with kidney problems use Sequest?

A: Regulatory documents include warnings that caution may be necessary for individuals with kidney disease due to a reported increased risk of developing electrolyte imbalances, such as hyperchloremic acidosis.


Q: Can you take Sequest if you have a known history of liver issues?

A: While the medicine is strictly prohibited in cases of complete biliary obstruction, regulatory cautions indicate that for patients with a history of liver disease, risks should be reviewed with a healthcare provider.


Q: What is the maximum duration a person can be on Sequest, according to trials?

A: Clinical trials evaluating the drug's effect on heart health have followed participants for several years. While long-term use is common, there is no single maximum regulatory duration specified for treatment.


Q: Can Sequest be taken long-term, and are there risks?

A: Clinical studies have involved participants taking the medicine for several years. However, official information notes that regular monitoring may be considered due to the risk of the drug affecting the body's absorption of fat-soluble vitamins (A, D, E, K).


Q: What kind of monitoring is needed while a person is taking Sequest?

A: Regulatory guidelines suggest that regular monitoring may be necessary. This typically includes blood tests to determine serum cholesterol and triglyceride concentrations, and vitamin levels may also be checked due to the risk of absorption interference.


Q: Does Sequest have a 'black box' warning?

A: No, the official U.S. Prescribing Information for this medication does not currently contain a Boxed Warning, which is often referred to as a Black Box Warning.


Q: Why does the packaging for Sequest have a special warning?

A: The regulatory information contains warnings regarding rare but serious events. These include the risk of complete or partial intestinal obstruction and an increased bleeding tendency due to long-term use affecting Vitamin K absorption.


Q: What if I experience a rare side effect mentioned on the list?

A: Official patient information states that a healthcare provider should be contacted immediately if serious effects occur. These include symptoms such as severe stomach pain, unusual bleeding or bruising, or black, bloody, or tarry stools.


Q: Is it true that Sequest can cause vision problems?

A: Rare instances of night blindness, a vision-related issue, have been reported in association with the drug. This is linked to the risk of Vitamin A deficiency associated with long-term use.


Q: Why are people talking about Sequest and high blood pressure?

A: The official interaction profile lists interactions with several common blood pressure medications, such as thiazide diuretics and propranolol. This is because the resin can affect the absorption of these other oral drugs.

How should Sequest be stored and disposed of?

Official Storage and Disposal Requirements

Cholestyramine (Sequest) powder must be stored according to specific regulatory guidelines to maintain its stability.

Storage Component Requirement
Temperature Controlled Room Temperature (20 C to 25 C).
Protection Keep protected from excessive heat and moisture.
Container Must remain in the original container, kept tightly closed.
Child Safety Keep out of the sight and reach of children.

For disposal, the product should be discarded following official guidelines for unused medicines, such as utilizing a drug take-back program. If a take-back option is unavailable, the powder may be mixed with an undesirable substance before being placed into household trash. The medication is not recommended for disposal by flushing down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sequest found in:

A-Z Index: